<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40953861</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of a novel intervention (Super Rehab) in overweight patients with atrial fibrillation (SuRe AF): protocol for a randomised controlled trial.</ArticleTitle><Pagination><StartPage>e103090</StartPage><MedlinePgn>e103090</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e103090</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2025-103090</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Atrial fibrillation (AF) is the most common sustained arrhythmia worldwide, associated with significant morbidity, mortality and healthcare utilisation. AF rhythm control strategies demonstrate attrition with time. A number of modifiable AF risk factors contribute to an atrial cardiomyopathy culminating in incident AF but importantly also recurrence. We propose that a novel multidisciplinary lifestyle intervention (Super Rehab, SR) may improve symptoms and AF burden.</AbstractText><AbstractText Label="METHODS AND ANALYSIS" NlmCategory="METHODS">This is a single-centre, randomised controlled study. Patients aged &#x2265;18 years with a body mass index &#x2265;27&#x2009;kg/m<sup>2</sup> with paroxysmal or persistent AF will be randomised 1:1 to National Health Service (NHS) usual care (UC) or to SR (together with NHS UC). SR incorporates high-intensity exercise, personalised dietary advice and AF risk factor modification. SR will be undertaken over 12 months. In addition to baseline assessments, follow-up assessments will occur at the 6, 12 and 15-month time points. The primary outcome will be the difference in AF symptom burden at 12 months between groups. Secondary outcomes include AF burden (assessed by an implantable cardiac monitor), changes to cardiac structure and function and computed tomography-based assessment of epicardial adipose tissue.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION" NlmCategory="BACKGROUND">Ethics approval was granted by London-Chelsea Research Ethics Committee (reference: 22/LO/0479 22/08/2022). All participants will provide written informed consent prior to enrolment. Study findings will be disseminated via presentations to relevant stakeholders, national and international conferences and open-access peer-reviewed research publications. A summary will also be communicated to the participants.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">ClinicalTrials.gov ID NCT05596175.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-0670-2567</Identifier><AffiliationInfo><Affiliation>Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK david.murphy12@nhs.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graby</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8753-1343</Identifier><AffiliationInfo><Affiliation>Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Mathematics, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peacock</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abramik</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antoniades</LastName><ForeName>Charalambos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Jonathan Carl Luis</ForeName><Initials>JCL</Initials><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Radiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Dylan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department for Health, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khavandi</LastName><ForeName>Ali</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cardiology, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05596175</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050177" MajorTopicYN="Y">Overweight</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005081" MajorTopicYN="Y">Exercise Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008019" MajorTopicYN="N">Life Style</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="N">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CARDIOLOGY</Keyword><Keyword MajorTopicYN="N">Exercise</Keyword><Keyword MajorTopicYN="N">Rehabilitation medicine</Keyword></KeywordList><CoiStatement>Competing interests: DM reports being in receipt of expenses and physician fees from HeartFlow. JG reports speaker fees from Sanofi. JCLR reports consulting fees from NHSX, speakers fees from Sanofi, physician services from HeartFlow and is co-founder and shareholder of Heart &amp; Lung Imaging LTD, all outside the submitted work. CA is a founder, shareholder and director of Caristo Diagnostics, a CT image analysis company providing perivascular fat attenuation index (FAI) analysis. FAI is subject to patent US10,695,023B2 and patent applications PCT/GB2017/053262, GB2018/1818049.7, GR20180100490 and GR20180100510 through exclusive license to Caristo Diagnostics. All other authors declare that they have no competing interests</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>20</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>15</Day><Hour>20</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40953861</ArticleId><ArticleId IdType="pmc">PMC12434741</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2025-103090</ArticleId><ArticleId IdType="pii">bmjopen-2025-103090</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lane DA, Skjoth F, Lip GYH, et al. Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in primary care. J Am Heart Assoc. 2017;6:e005155. doi: 10.1161/JAHA.116.005155.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.116.005155</ArticleId><ArticleId IdType="pmc">PMC5524079</ArticleId><ArticleId IdType="pubmed">28455344</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746&#x2013;51. doi: 10.1093/eurheartj/eht280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/eht280</ArticleId><ArticleId IdType="pmc">PMC3858024</ArticleId><ArticleId IdType="pubmed">23900699</ArticleId></ArticleIdList></Reference><Reference><Citation>BHF  UK Factsheet. British Heart Foundation. 2024. https://www.bhf.org.uk Available.</Citation></Reference><Reference><Citation>Benjamin EJ, Wolf PA. Impact of atrial fibrillation on the risk of death: the framingham heart study. Circ. 1998;98:946&#x2013;52. doi: 10.1161/01.cir.98.10.946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.98.10.946</ArticleId><ArticleId IdType="pubmed">9737513</ArticleId></ArticleIdList></Reference><Reference><Citation>Velleca M, Costa G, Goldstein L, et al. A review of the burden of atrial fibrillation: understanding the impact of the new millennium epidemic across Europe. EMJ Cardiol. 2019;7:110&#x2013;8. doi: 10.33590/emjcardiol/10310292.</Citation><ArticleIdList><ArticleId IdType="doi">10.33590/emjcardiol/10310292</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf PA, Dawber TR, Thomas HE, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the framingham study. Neurology. 1978;28:973&#x2013;7. doi: 10.1212/wnl.28.10.973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.28.10.973</ArticleId><ArticleId IdType="pubmed">570666</ArticleId></ArticleIdList></Reference><Reference><Citation>Anter E, Jessup M, Callans DJ, et al. Atrial fibrillation and heart failure. Treatment considerations for a dual epidemic. Circ. 2009;119:2516&#x2013;25. doi: 10.1161/CIRCULATIONAHA.108.821306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.108.821306</ArticleId><ArticleId IdType="pubmed">19433768</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdett P, Lip GYH. Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation &#x2013; related costs. Eur Heart J Qual Care Clin Outcomes. 2022;8:187&#x2013;94. doi: 10.1093/ehjqcco/qcaa093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjqcco/qcaa093</ArticleId><ArticleId IdType="pubmed">33346822</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE)  Atrial fibrillation: diagnosis and management NG196. London: NICE. 2021.  [24-Feb-2021]. https://www.nice.org.uk/guidance/ng196 Available. Accessed.</Citation><ArticleIdList><ArticleId IdType="pubmed">34165935</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks G, Potpara T, Dagres N. Corrigendum to: 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2021;42:507. doi: 10.1093/eurheartj/ehaa798.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa798</ArticleId><ArticleId IdType="pubmed">33029625</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circ. 2012;125:381&#x2013;9. doi: 10.1161/circulationaha.111.019927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circulationaha.111.019927</ArticleId><ArticleId IdType="pubmed">22249528</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan G-A, Martinez-Rubio A, Agewall S, et al. Antiarrhythmic drugs&#x2013;clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP) EP Europace. 2018;20:731&#x2013;732an. doi: 10.1093/europace/eux373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eux373</ArticleId><ArticleId IdType="pubmed">29438514</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenter A, Graby J, Medland R, et al. Efficacy of DC cardoiversion for atrial fibrillation: a large retrospective observational study. Heart. 2019;105 doi: 10.1136/heartjnl-2019-BCS.36.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/heartjnl-2019-BCS.36</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo C. How the new technologies and tools will change the electrophysiology of the future. Eur Heart J Suppl. 2023;25:C249&#x2013;52. doi: 10.1093/eurheartjsupp/suad024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartjsupp/suad024</ArticleId><ArticleId IdType="pmc">PMC10132569</ArticleId><ArticleId IdType="pubmed">37125295</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung LWM, Imhoff RJ, Marshall HJ, et al. Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom. J Cardiovasc Electrophysiol. 2022;33:164&#x2013;75. doi: 10.1111/jce.15317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.15317</ArticleId><ArticleId IdType="pmc">PMC9300178</ArticleId><ArticleId IdType="pubmed">34897897</ArticleId></ArticleIdList></Reference><Reference><Citation>Benali K, Khairy P, Hammache N, et al. Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2023;81:2089&#x2013;99. doi: 10.1016/j.jacc.2023.03.418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2023.03.418</ArticleId><ArticleId IdType="pubmed">37225362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesan AN, Shipp NJ, Brooks AG, et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc. 2013;2:e00459. doi: 10.1161/JAHA.112.004549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.112.004549</ArticleId><ArticleId IdType="pmc">PMC3647286</ArticleId><ArticleId IdType="pubmed">23537812</ArticleId></ArticleIdList></Reference><Reference><Citation>Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18:1455&#x2013;90. doi: 10.1093/europace/euw161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euw161</ArticleId><ArticleId IdType="pmc">PMC6392440</ArticleId><ArticleId IdType="pubmed">27402624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nabauer M, Gerth A, Limbourg T, et al. The registry of the German competence NETwork on atrial fibrillation: patient characteristics and initial management. Europace. 2009;11:423&#x2013;34. doi: 10.1093/europace/eun369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eun369</ArticleId><ArticleId IdType="pmc">PMC2659602</ArticleId><ArticleId IdType="pubmed">19153087</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao LZ, Wen XY, Zhang SZ, et al. Hypertension and atrial fibrillation: a study on epidemiology and mendelian randomization causality. Front Cardiovasc Med. 2021;8:644405. doi: 10.3389/fcm.2021.644405.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcm.2021.644405</ArticleId><ArticleId IdType="pmc">PMC8021766</ArticleId><ArticleId IdType="pubmed">33834045</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisters R, Nieuwlatt R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010;55:725&#x2013;31. doi: 10.1016/j.jacc.2009.11.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2009.11.040</ArticleId><ArticleId IdType="pubmed">20170808</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg JS, Shabanov V, Ponomarev D, et al. Effect of renal denervation and catheter ablation vs catheter ablation alone on atrial fibrillation recurrence among patients with paroxysmal atrial fibrillation and hypertension: the ERADICATE-AF randomized clinical trial. JAMA. 2020;323:248&#x2013;55. doi: 10.1001/jama.2019.21187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.21187</ArticleId><ArticleId IdType="pmc">PMC6990678</ArticleId><ArticleId IdType="pubmed">31961420</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J. 2008;29:1662&#x2013;9. doi: 10.1093/eurheartj/ehn214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehn214</ArticleId><ArticleId IdType="pubmed">18515807</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto ME, Belohlavek M, Romero-Corral A, et al. Comparison of cardiac structural and functional changes in obese otherwise healthy adults with versus without obstructive sleep apnea. Am J Cardiol. 2007;99:1298&#x2013;302. doi: 10.1016/j.amjcard.2006.12.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2006.12.052</ArticleId><ArticleId IdType="pubmed">17478161</ArticleId></ArticleIdList></Reference><Reference><Citation>Somers VK, Dyken ME, Clary MP, et al. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96:1897&#x2013;904. doi: 10.1172/JCI118235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI118235</ArticleId><ArticleId IdType="pmc">PMC185826</ArticleId><ArticleId IdType="pubmed">7560081</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circ. 2003;20:2589&#x2013;94. doi: 10.1161/01.cir.0000068337.25994.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.cir.0000068337.25994.21</ArticleId><ArticleId IdType="pubmed">12743002</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Wang ZW, Li J, et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace. 2014;16:1309&#x2013;14. doi: 10.1093/europace/euu066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euu066</ArticleId><ArticleId IdType="pubmed">24696222</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84&#x2013;93. doi: 10.1016/j.yjmcc.2015.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2015.12.011</ArticleId><ArticleId IdType="pmc">PMC4718740</ArticleId><ArticleId IdType="pubmed">26705059</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe M, Yokoshiki H, Mitsuyama H, et al. Conduction and refractory disorders in the diabetic atrium. Am J Physiol Heart Circ Physiol. 2012;303:H86&#x2013;95. doi: 10.1152/ajpheart.00010.2012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00010.2012</ArticleId><ArticleId IdType="pubmed">22561303</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnellan E, Aagaard P, Kanj M, et al. Association between pre-ablation glycemic control and outcomes among patients with diabetes undergoing atrial fibrillation ablation. JACC: Clinical Electrophysiology. 2019;5:897&#x2013;903. doi: 10.1016/j.jacep.2019.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2019.05.018</ArticleId><ArticleId IdType="pubmed">31439289</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE)  Obesity: identification, assessment and management. NICE clinical knowledge summary 2023. London: NICE. 2023.  [24-Feb-2023]. https://cks.nice.org.uk/topics/obesity/management/ Available. Accessed.</Citation><ArticleIdList><ArticleId IdType="pubmed">36719951</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte M, Petraglia L, Cabaro S, et al. Epicardial adipose tissue and cardiac arrhythmias: Focus on atrial fibrillation. Front Cardiovasc Med. 2022;9:932262. doi: 10.3389/fcvm.2022.932262.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.932262</ArticleId><ArticleId IdType="pmc">PMC9280076</ArticleId><ArticleId IdType="pubmed">35845044</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CX, Sullivan T, Sun MT, et al. Obesity and the risk of incident, post-operative, and post-ablation atrial fibrillation: A meta-analysis of 626,603 individuals in 51 studies. JACC Clin Electrophysiol. 2015;1:139&#x2013;52. doi: 10.1016/j.jacep.2015.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacep.2015.04.004</ArticleId><ArticleId IdType="pubmed">29759357</ArticleId></ArticleIdList></Reference><Reference><Citation>Peigh G, Wasserlauf J, Vogel K, et al. Impact of pre-ablation weight loss on the success of catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2021;32:2097&#x2013;104. doi: 10.1111/jce.15141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jce.15141</ArticleId><ArticleId IdType="pmc">PMC9305992</ArticleId><ArticleId IdType="pubmed">34191371</ArticleId></ArticleIdList></Reference><Reference><Citation>Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA - J Am Med Assoc. 2013;310:2050&#x2013;60. doi: 10.1001/jama.2013.280521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.280521</ArticleId><ArticleId IdType="pubmed">24240932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak RK, Elliott A, Middeldorp ME, et al. Impact of CARDIOrespiratory FITness on arrhythmia recurrence in obese individuals with atrial fibrillation: the CARDIO-FIT Study. J Am Coll Cardiol. 2015;66:985&#x2013;96. doi: 10.1016/j.jacc.2015.06.488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.06.488</ArticleId><ArticleId IdType="pubmed">26113406</ArticleId></ArticleIdList></Reference><Reference><Citation>Garnvik LE, Malmo V, Janszky I, et al. Physical activity, cardiorespiratory fitness, and cardiovascular outcomes in individuals with atrial fibrillation: the HUNT study. Eur Heart J. 2020;41:1467&#x2013;75. doi: 10.1093/eurheartj/ehaa032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa032</ArticleId><ArticleId IdType="pmc">PMC7320825</ArticleId><ArticleId IdType="pubmed">32047884</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: The ARREST-AF cohort study. J Am Coll Cardiol. 2014;64:2222&#x2013;31. doi: 10.1016/j.jacc.2014.09.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2014.09.028</ArticleId><ArticleId IdType="pubmed">25456757</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp ME, Pathak RK, Meredith M, et al. PREVEntion and regReSsive effect of weight-loss and risk factor modification on atrial fibrillation: The REVERSE-AF study. Europace. 2018;20:1929&#x2013;35. doi: 10.1093/europace/euy117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euy117</ArticleId><ArticleId IdType="pubmed">29912366</ArticleId></ArticleIdList></Reference><Reference><Citation>Pathak RK, Middeldorp ME, Meredith M, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort. J Am Coll Cardiol. 2015;65:2159&#x2013;69. doi: 10.1016/j.jacc.2015.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2015.03.002</ArticleId><ArticleId IdType="pubmed">25792361</ArticleId></ArticleIdList></Reference><Reference><Citation>Council B, Bath NES, Somerset NE. Healthy Weight Strategy Bath and North East Somerset 2015 to 2020. 2015. https://www.bathnes.gov.uk/sites/default/files/banes_draft_healthy_weight_strategy_document.pdf Available.</Citation></Reference><Reference><Citation>West HW, Siddique M, Williams MC, et al. Deep-learning for epicardial adipose tissue assessment with computed tomography: implications for cardiovascular risk prediction. JACC Cardiovasc Imaging. 2023;16:800&#x2013;16. doi: 10.1016/j.jcmg.2022.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcmg.2022.11.018</ArticleId><ArticleId IdType="pmc">PMC10663979</ArticleId><ArticleId IdType="pubmed">36881425</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson D, Markovitch D, Betts JA, et al. Time course of changes in inflammatory markers during a 6-mo exercise intervention in sedentary middle-aged men: a randomized-controlled trial. J Appl Physiol. 2010;108:769&#x2013;79. doi: 10.1152/japplphysiol.00822.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00822.2009</ArticleId><ArticleId IdType="pubmed">20368384</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JL, Holland DJ, Spathis JG, et al. Guidelines for the delivery and monitoring of high intensity interval training in clinical populations. Prog Cardiovasc Dis. 2019;62:140&#x2013;6. doi: 10.1016/j.pcad.2019.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pcad.2019.01.004</ArticleId><ArticleId IdType="pubmed">30685470</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K, Wahome E, Tsiachristas A, et al. Inflammatory risk and cardiovascular events in patients without obstructive coronary artery disease: the ORFAN multicentre, longitudinal cohort study. Lancet. 2024;403:2606&#x2013;18. doi: 10.1016/S0140-6736(24)00596-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00596-8</ArticleId><ArticleId IdType="pmc">PMC11664027</ArticleId><ArticleId IdType="pubmed">38823406</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>